This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IPO Lessons From Pandora

Investors are still fairly leery of small companies going public.

These days investors are looking to companies that have an eye on the future -- those pioneering in digital media, mobile technology, clean tech and alternative energy, says Kathleen Smith, principal of IPO investment and research firm Renaissance Capital.

"But the market still needs track records," Smith says. Unlike what happened in the dot-com bubble, when Internet companies were barely making revenue, let alone profit, the key is to have positive revenue and earnings.

"The only ones that have managed to get through that do have losses are the biotech firms," Smith says. "They really are a different category. Investors are willing to look at that, but many of these IPOs come at great discounts of what the companies are hoping to raise [primarily because] some venture capitalists who invest in biotech firms are very impatient and want liquidity fast."

Of the 24 U.S. IPOs that have priced this year, the average return has been 10.5%, according to Renaissance Capital's website. Seven were in the health care sector, primarily biotech.

Excluding biotech, small firms with deals over $50 million are outperforming the larger IPOs this year, Smith says.

Smith notes that of the five companies already trading below their IPO prices, four underwent IPOs of less than $50 million and three are biotech firms.
  • Of the five companies, Tornier(TRNX), an Amsterdam-based orthopedic device specialist, was the largest deal at $166 million. Still, the stock closed Tuesday at $18.45 -- below the $19 IPO price it announced Feb. 2.
  • AcelRx Pharmaceuticals(ACRX - Get Report), which debuted Friday, priced 8 million shares at $5 per share -- well below its expected trading range. The IPO raised gross proceeds of about $40 million. The stock closed Tuesday at $4.31.
  • Trunkbow International Holdings(TBOW), a Beijing-based mobile application provider that began trading Feb. 3, also priced its stock below the previously expected trading range at $5 per share. The IPO raised gross proceeds of $20 million. The stock closed Tuesday at $4.62.
  • Pacira Pharmaceuticals(PCRX - Get Report) priced its $32 million IPO at $7 a share Feb. 3. The stock closed on Tuesday at $6.91.
  • Kips Bay Medical(KIPS) of Minneapolis priced shares at $8, raising gross proceeds of about $16.5 million. The stock closed Tuesday at $7.93.

-- Written by Laurie Kulikowski in New York.

To contact the writer of this article, click here: Laurie Kulikowski.

>To submit a news tip, email:


Follow on Twitter and become a fan on Facebook.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
KIPS $0.01 16.39%
NYX $0.00 0.00%
TBOW $1.45 0.00%
TRNX $0.00 0.00%
ACRX $3.38 1.81%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs